8-K: Cencora Reports Strong Q3 2026 Results, Raises Guidance

Cencora announced robust third-quarter fiscal 2026 results, featuring a 5.1% year-over-year revenue increase to $84.8 billion and a 12.0% rise in adjusted diluted EPS to $4.48, leading to an upward revision of full-year EPS guidance.

Summary

• Cencora reported third-quarter fiscal 2026 revenue of $84.8 billion, a 5.1% increase year-over-year.
• GAAP diluted EPS was $3.94, and Adjusted Diluted EPS was $4.48, up 12.0% from the prior year.
• The company raised its fiscal year 2026 Adjusted Diluted EPS guidance to a range of $17.75 to $17.95.
• Cencora repurchased $1 billion of its shares in the third fiscal quarter.
• U.S. Healthcare Solutions revenue grew 4.9%, and International Healthcare Solutions revenue grew 5.9%.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, increased EPS, and a raised full-year guidance, indicating solid operational performance and confidence in future prospects.

Positives

• Revenue increased by 5.1% year-over-year to $84.8 billion in Q3 fiscal 2026.
• Adjusted Diluted EPS increased by 12.0% to $4.48 in Q3 fiscal 2026.
• Full-year fiscal 2026 Adjusted Diluted EPS guidance was raised to $17.75 $17.95.
• Gross profit increased by 24.1% year-over-year to $3.6 billion in Q3 fiscal 2026.
• Operating income increased by 29.1% year-over-year to $1.1 billion in Q3 fiscal 2026.
• The company repurchased $1 billion of shares in Q3 fiscal 2026, exceeding previous expectations.
• Good Neighbor Pharmacy ranked #1 in Customer Satisfaction in the J.D. Power 2026 U.S. Pharmacy Study for the fourteenth time.

Negatives

• Operating expenses increased by 21.9% year-over-year, primarily due to the OneOncology acquisition.
• Net interest expense increased by $58.9 million due to senior note and term loan issuance for the OneOncology acquisition.
• Increased sales of GLP-1 products, while contributing to revenue, have lower gross profit margins.

Risks

• The company's actual results could differ materially from forward-looking statements due to various risks and uncertainties detailed in its SEC filings.
• Increased sales of GLP-1 products, while driving revenue, have lower gross profit margins, potentially impacting profitability.
• The loss of an oncology customer in 2025 continues to offset revenue growth in the U.S. Healthcare Solutions segment.

Future Outlook

The company has raised its fiscal year 2026 Adjusted Diluted EPS guidance to a range of $17.75 to $17.95, reflecting confidence in continued strong performance and opportunistic share repurchases.

Management Comments

• "Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members."
• "Our strong performance and confidence in our outlook enabled us to raise our fiscal 2026 guidance, underscoring the value we deliver for our stakeholders."
• "Our investments in specialty, digital transformation and talent are strengthening our ability to support our customers across the healthcare ecosystem while positioning Cencora for sustainable long-term growth."
• "The capabilities we have built, and the strength of our core businesses provide a solid foundation for continued growth as we close fiscal 2026."

Industry Context

StockSavvy.ai notes that Cencora's performance aligns with broader trends in the pharmaceutical distribution and solutions sector, characterized by increasing demand for specialty drugs and digital transformation initiatives. The acquisition of OneOncology positions the company to capitalize on the growing oncology market.

Comparison to Industry Standards

• Cencora's revenue growth of 5.1% in Q3 FY26 is solid within the pharmaceutical distribution sector, which can experience moderate single-digit growth.
• The adjusted diluted EPS growth of 12.0% outpaces many peers, indicating strong operational leverage and effective cost management.
• The company's strategic focus on specialty pharmaceuticals and digital solutions is a common theme among leading distributors aiming to enhance value-added services.
• Competitors like McKesson and Cardinal Health also focus on expanding their specialty pharmacy services and supply chain solutions, though Cencora's specific integration of OneOncology offers a unique angle in the oncology space.

Management Changes

Legal Proceedings

• A $102.0 million reduction in opioid liability was recognized due to the dismissal of opioid litigation in Q3 FY26.
• An $86.8 million credit related to a derivative lawsuit settlement was recognized in the nine months ended June 30, 2026.

Stakeholder Impact

• Shareholders benefit from increased EPS and a raised full-year guidance, alongside $1 billion in share repurchases and a declared quarterly dividend.
• Customers are expected to benefit from continued investment in specialty, digital transformation, and talent, strengthening Cencora's ability to support the healthcare ecosystem.
• Employees may see continued investment in talent development and a stable outlook for long-term growth.

Next Steps

• Continue execution of pharmaceutical-centric strategy.
• Invest in specialty, digital transformation, and talent.
• Support customers across the healthcare ecosystem.
• Focus on sustainable long-term growth.
• Attend upcoming investor events: Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference.

Key Dates

Recommendation

The company delivered better-than-expected results and raised guidance, which is positive. However, the increased operating expenses and interest expense related to the OneOncology acquisition, along with the lower margins on GLP-1 sales, warrant a cautious approach. The stock appears to be fairly valued given these factors, suggesting a 'hold' rating until further clarity on integration benefits and margin improvement.

Keywords

Cencora, Healthcare Solutions, Pharmaceuticals, Revenue, Earnings Per Share, Guidance, Acquisition, OneOncology